| Background:Coronary heart disease is one of the major cardiovascular diseases,which is often associated with a variety of complications. Diabetes is one of its riskfactors, but also its common complications. The number of diabetic patients in Chinaranks first in the world. Coronary heart disease is the most common cause of death indiabetic patients, therefore, it is very important to strengthen screening abnormalglucose metabolism of glucose and reasonable intervention to improve the prognosisof patients with coronary artery disease. Macrophage migration inhibitory factor thatis a pleiotropic cytokine and an important media of immune and inflammatoryresponses，plays an important role in the development of coronary heart disease anddiabetes. Exploring the effect of macrophage migration inhibitory factor on coronaryheart disease companying with diabetes will help to clarify the role of MIF in thepathogenesis mechanisms, and it can be interventional target for the effectivetreatments.Dipeptidyl peptidase4widely presents in the plasma, kidneys, gastrointestinaltracts, lymphatic tissues and other tissues in vivo, that is a multifunctional proteolyticenzyme. It is a new target for the treatment of type2diabetes since dipeptidylpeptidase4may decompose some protein just like Glucagon-like peptide-1. DPP-4inhibitors acts as a novel oral hypoglycemic agents, which gradually become the hotpoint in recent years. With the extensive use of these drugs, more and moreadvantages except its hypoglycemic role in research have been paid close attention.Objective:We detected the concentration of MIF that exposed in peripheral bloodserum in the patients with coronary heart disease, coronary artery disease withdiabetes, coronary artery disease with diabetes after three months of treatment byDPP-4inhibitors. We tried to explore the role of MIF in coronary heart disease withdiabetes, and to clarify DPP-4inhibitors’ other effects besides lowering blood sugarconcentration in diabetic patients with coronary heart disease by adjusting the MIFconcentration. Methods:60patients Hospitalized in the department of Cardiology in the secondhospital of Jilin University from February2013to January2014(27males，33females)were selected，they were divided into3groups, coronary heart disease group(CHD),coronary heart disease with diabetes group，coronary heart disease with diabetesgroup at the3months after treatment by DPP-4inhibitors, each group included30patients. Each patient’s body mass index, glutamic-pyruvic transaminases,glutamic-oxaloacetic transaminase, glycosylated hemoglobin, riglycerides, lowdensity lipoprotein，high density lipoprotein are detected. The MIF serum levels ofeach group are examined by enzyme-linked immunosorbent assay method, statisticalanalysis was used to analyzed the determination of the test results. All the data wereexpressed as means±SD. The differences between two groups were analyzed by t-test.All statistical analysis was performed using SPSS19.0software and P<0.05wasstatistically significant.Results:1.Compared with coronary heart disease group，the MIF concentration incoronary heart disease with diabetes group increased，difference was statisticallysignificant (P <0.05).2.The MIF concentration in coronary heart disease with diabetes group weresignificantly decreased after the treatment by DPP-4inhibitors，difference wasstatistically significant (P <0.05).Conclusion:1.The MIF plays an important role in coronary heart disease with diabetes，and itmay be an important factor in progressing of high blood glucose acceleratingcoronary artery disease.2.DPP-4inhibitor can effectively reduce blood glucose levels and decrease theMIF concentration， they may exert anti-inflammatory effects hypoglycemicsimultaneously by reducing the MIF concentration. |
PDF Full Text Request